Antonio Marra

Aug 2, 2024 | nature.com | Antonio Marra |Sarat Chandarlapaty |Shanu Modi

Correction to: Nature Reviews Clinical Oncology https://doi.org/10.1038/s41571-023-00849-9, published online 8 January 2024. In the version of the article initially published, there was an error in the second paragraph of the introduction, where “mouse erbB2” has been corrected to “human HER2” in the sentence now reading “Among these, a mouse mAb targeting human HER2 demonstrated remarkable preclinical activity…” in the HTML and PDF versions of article.

Mar 21, 2024 | jamanetwork.com | Stefania Morganti |Antonio Marra |Federico II

Abstract Importance  Poly(adenosine diphosphate–ribose) polymerase (PARP) inhibitors have revolutionized the treatment of patients with germline BRCA1/2-associated breast cancer, representing the first targeted therapy capable of improving outcomes in patients with hereditary tumors. However, resistance to PARP inhibitors occurs in almost all patients.

Jan 8, 2024 | nature.com | Antonio Marra |Sarat Chandarlapaty |Shanu Modi

AbstractAmplification and/or overexpression of ERBB2, the gene encoding HER2, can be found in 15–20% of invasive breast cancers and is associated with an aggressive phenotype and poor clinical outcomes.

Jul 13, 2023 | nature.com | Jing Yu |Beth Clark |Jeffrey L. Fine |Adrian Lee |Steffi Oesterreich |Thais Basili | +5 more

AbstractThis study describes “lobular-like invasive mammary carcinomas” (LLIMCas), a group of low- to intermediate-grade invasive mammary carcinomas with discohesive, diffusely infiltrative cells showing retained circumferential membranous immunoreactivity for both E-cadherin and p120. We analyzed the clinical-pathologic features of 166 LLIMCas compared to 104 classical invasive lobular carcinomas (ILCs) and 100 grade 1 and 2 invasive ductal carcinomas (IDCs).